CD274 and non-small cell lung carcinoma: In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab elicited longer PFS than did platinum-based chemotherapy in patients with treatment-naïve, advanced non-small-cell lung cancer with a PD-L1 tumor proportion score of ≥50%.